Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.